William Blair Issues Positive Estimate for Agenus Earnings

Agenus Inc. (NASDAQ:AGEN) – Analysts at William Blair boosted their Q1 2025 EPS estimates for Agenus in a research note issued to investors on Tuesday, March 11th. William Blair analyst M. Phipps now anticipates that the biotechnology company will earn ($1.17) per share for the quarter, up from their previous forecast of ($1.31). The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. William Blair also issued estimates for Agenus’ Q2 2025 earnings at ($0.90) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($3.48) EPS, FY2026 earnings at ($2.58) EPS and FY2027 earnings at ($2.51) EPS.

A number of other research firms have also weighed in on AGEN. Robert W. Baird lowered their price target on shares of Agenus from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Wednesday. HC Wainwright reissued a “neutral” rating on shares of Agenus in a report on Wednesday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $8.75.

Agenus Stock Down 10.2 %

Agenus stock opened at $1.68 on Friday. The firm has a fifty day moving average of $3.23 and a 200-day moving average of $3.84. The firm has a market capitalization of $39.29 million, a P/E ratio of -0.15 and a beta of 1.23. Agenus has a 52-week low of $1.67 and a 52-week high of $19.69.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.36) by $0.32. The business had revenue of $26.84 million during the quarter, compared to analyst estimates of $30.09 million.

Institutional Trading of Agenus

Several hedge funds have recently bought and sold shares of AGEN. Corton Capital Inc. bought a new stake in Agenus in the 4th quarter valued at about $36,000. Virtu Financial LLC acquired a new position in Agenus during the 4th quarter valued at about $51,000. Apollon Wealth Management LLC acquired a new position in Agenus during the 4th quarter valued at about $55,000. EP Wealth Advisors LLC acquired a new position in Agenus during the 3rd quarter valued at about $55,000. Finally, Bank of Montreal Can acquired a new position in Agenus during the 4th quarter valued at about $69,000. 61.46% of the stock is currently owned by institutional investors.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.